Astragaloside IV

Pharmacology & Research

Astragaloside IV (AS-IV) is the marker cycloartane saponin of astragalus (Astragalus membranaceus, huang qi), and the single molecule most often credited with the root’s traditional cardiac, kidney and “tonic” reputation. The literature on it is large but almost entirely preclinical — hundreds of cell and rodent studies spanning cardioprotection, anti-fibrosis, diabetic nephropathy, neuroprotection and immunomodulation, aggregated in several reviews and preclinical meta-analyses ^{3,4,5Reference 3Li L et al. · 2017ReviewResearch review on the pharmacological effects of astragaloside IV — reviewView study →Reference 4Liang Y et al. · 2023ReviewPharmacological Effects of Astragaloside IV: A Review — reviewView study →Reference 5Zhuang Z et al. · 2019Meta-analysisAstragaloside IV Exerts Cardioprotection in Animal Models of Viral Myocarditis: A Preclinical Systematic Review and Meta-Analysis — meta-analysis of animal modelsView study →}. The decisive caveat sits underneath all of it: the isolated molecule is a large, poorly permeable saponin with oral bioavailability of only ~2–3% in rats ^{1Reference 1Gu Y et al. · 2004In vitroTransport and bioavailability studies of astragaloside IV, an active ingredient in Radix Astragali — rat/in vivo, Caco-2 in vitroView study →}, which is why the huge in-vitro/in-vivo signal has never been shown to reproduce in a human trial of the isolated compound. Every application below rests on animal or cell work; any human evidence for astragalus is whole-extract, not molecule-level, and does not transfer to AS-IV.

1. Cardioprotection

The most-studied use, and the strongest of a preclinical-only set. In rat models the isolated molecule improves cardiac function and limits injury: a preclinical systematic review and meta-analysis of 19 studies (489 animals) in heart failure found AS-IV improved ejection fraction and other function indices dose-dependently ^{7Reference 7Zhang Z et al. · 2023Meta-analysisEffect of Astragaloside IV on improving cardiac function in rats with heart failure: a preclinical systematic review and meta-analysis — meta-analysis of rat modelsView study →}, and a separate meta-analysis in viral-myocarditis models found reduced mortality, myocardial inflammation and cardiac-enzyme release ^{5Reference 5Zhuang Z et al. · 2019Meta-analysisAstragaloside IV Exerts Cardioprotection in Animal Models of Viral Myocarditis: A Preclinical Systematic Review and Meta-Analysis — meta-analysis of animal modelsView study →}. Mechanistic reviews attribute this to antioxidant, anti-inflammatory, calcium-handling and anti-apoptotic effects on cardiomyocytes and vascular endothelium ^{6,3Reference 6Yang C et al. · 2023ReviewReview on the protective mechanism of astragaloside IV against cardiovascular diseases — reviewView study →Reference 3Li L et al. · 2017ReviewResearch review on the pharmacological effects of astragaloside IV — reviewView study →}.

Gap: every data point is animal — pooled rodent efficacy is not human efficacy, and the ~2–3% oral bioavailability ^{1Reference 1Gu Y et al. · 2004In vitroTransport and bioavailability studies of astragaloside IV, an active ingredient in Radix Astragali — rat/in vivo, Caco-2 in vitroView study →} means many studies dose by injection or at levels not achievable by mouth in people.

2. Diabetic nephropathy

The kidney-protective signal is the second-best-supported, and again rests on the isolated molecule in rodents. In streptozotocin-induced diabetic rats, AS-IV reduced proteinuria and protected podocytes from loss and foot-process effacement ^{9Reference 9Chen J et al. · 2014AnimalAstragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats — rat in vivoView study →}. A preclinical systematic review and meta-analysis (24 studies, 424 animals) found AS-IV slowed glomerular/tubular pathology, raised creatinine clearance and lowered blood urea nitrogen, serum creatinine and urinary albumin, acting through antifibrotic, antioxidant and anti-apoptotic mechanisms ^{8Reference 8Wang H et al. · 2020Meta-analysisProtective Effect and Possible Mechanisms of Astragaloside IV in Animal Models of Diabetic Nephropathy: A Preclinical Systematic Review and Meta-Analysis — meta-analysis of animal modelsView study →}.

Gap: consistent but entirely preclinical; no human trial of isolated AS-IV in diabetic kidney disease exists, and oral delivery of an active dose is the unsolved problem ^{1Reference 1Gu Y et al. · 2004In vitroTransport and bioavailability studies of astragaloside IV, an active ingredient in Radix Astragali — rat/in vivo, Caco-2 in vitroView study →}.

3. Anti-fibrotic

A broad, cross-organ preclinical signal built on one recurring mechanism. In bleomycin-induced pulmonary fibrosis in mice, the isolated molecule suppressed TGF-β1-driven epithelial–mesenchymal transition and reduced fibrotic markers ^{10Reference 10Qian W et al. · 2018In vitroAstragaloside IV modulates TGF-β1-dependent epithelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis — mouse in vivo / in vitroView study →}, and reviews collate similar antifibrotic effects across lung, kidney, liver and heart via TGF-β/Smad and related pathways ^{4Reference 4Liang Y et al. · 2023ReviewPharmacological Effects of Astragaloside IV: A Review — reviewView study →}.

Gap: the mechanism is coherent across models but the evidence is cell- and rodent-level only, with no human anti-fibrosis data for the isolated compound ^{4,10Reference 4Liang Y et al. · 2023ReviewPharmacological Effects of Astragaloside IV: A Review — reviewView study →Reference 10Qian W et al. · 2018In vitroAstragaloside IV modulates TGF-β1-dependent epithelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis — mouse in vivo / in vitroView study →}.

4. Neuroprotection

Promising but the thinnest of the four, and assay-heavy. In rat cerebral ischemia–reperfusion, the isolated molecule attenuated blood-brain-barrier breakdown by preserving tight-junction proteins ^{11Reference 11Qu YZ et al. · 2009AnimalAstragaloside IV attenuates cerebral ischemia-reperfusion-induced increase in permeability of the blood-brain barrier in rats — rat in vivoView study →}, and separately reduced neuronal injury via JAK2/STAT3 signalling in an ischemia–reperfusion model ^{12Reference 12Xu Z et al. · 2020In vitroAstragaloside IV Alleviates Cerebral Ischemia-Reperfusion Injury by Activating the Janus Kinase 2 and Signal Transducer and Activator of Transcription 3 Signaling Pathway — rat in vivo / in vitroView study →}.

Gap: small rodent studies with varied models and routes; no human stroke data for isolated AS-IV, and CNS delivery of a poorly absorbed saponin is unaddressed ^{11,12Reference 11Qu YZ et al. · 2009AnimalAstragaloside IV attenuates cerebral ischemia-reperfusion-induced increase in permeability of the blood-brain barrier in rats — rat in vivoView study →Reference 12Xu Z et al. · 2020In vitroAstragaloside IV Alleviates Cerebral Ischemia-Reperfusion Injury by Activating the Janus Kinase 2 and Signal Transducer and Activator of Transcription 3 Signaling Pathway — rat in vivo / in vitroView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
Oxidative stress (ROS, SOD, antioxidant enzymes)	↓ ROS, ↑ endogenous antioxidant defence (rodent/in vitro)	cardioprotection, kidney, neuroprotection
NF-κB / inflammatory cytokines	suppressed pro-inflammatory signalling	cardio-, reno- and neuro-protection
TGF-β1 / Smad signalling	↓ epithelial–mesenchymal transition and fibrotic markers	anti-fibrotic effects across organs
Apoptosis regulators (Bax/Bcl-2, caspases)	anti-apoptotic in stressed cardiomyocytes, podocytes, neurons	cardio-, reno-, neuroprotection
JAK2 / STAT3	modulated to reduce ischemic neuronal injury (rat)	neuroprotection

Pharmacokinetics

This is the load-bearing section and the reason the vast preclinical body has not become human evidence. In the definitive rat study, the absolute oral bioavailability of astragaloside IV was ~2.2%: absorption from an aqueous solution was low, permeability across Caco-2 monolayers was very poor, and most of an oral dose was not absorbed ^{1Reference 1Gu Y et al. · 2004In vitroTransport and bioavailability studies of astragaloside IV, an active ingredient in Radix Astragali — rat/in vivo, Caco-2 in vitroView study →}. Notably, that same work found uptake was not affected by P-glycoprotein inhibitors and was not increased by bile-duct ligation — so the bottleneck is the molecule’s intrinsically poor passive permeability as a large, polar cycloartane saponin, not primarily active efflux ^{1Reference 1Gu Y et al. · 2004In vitroTransport and bioavailability studies of astragaloside IV, an active ingredient in Radix Astragali — rat/in vivo, Caco-2 in vitroView study →}. (Other reports do describe AS-IV as a P-gp substrate, so efflux may contribute; the primary transport study points to permeability as the dominant limit.) Preclinical pharmacokinetic and tissue-distribution work in rats and dogs confirms wide but low-level distribution consistent with this poor absorption ^{2Reference 2Zhang WD et al. · 2006AnimalPreclinical pharmacokinetics and tissue distribution of a natural cardioprotective agent astragaloside IV in rats and dogs — animal pharmacokineticsView study →}. The practical consequence: micromolar in-vitro potencies and injected rodent doses do not correspond to concentrations an oral human dose could reach, which is why isolate-level human efficacy remains unestablished.

Clinical trials

There are essentially no registered trials of the isolated compound — human data for astragalus are at the whole-extract level and do not establish anything about isolated AS-IV. All therapeutic evidence for the molecule is preclinical ^{3,4Reference 3Li L et al. · 2017ReviewResearch review on the pharmacological effects of astragaloside IV — reviewView study →Reference 4Liang Y et al. · 2023ReviewPharmacological Effects of Astragaloside IV: A Review — reviewView study →}.

Last checked: July 2026.

Toxicity & Safety

Astragaloside IV has a reassuring preclinical safety profile: reviews report no significant toxicity in standard animal testing, and repeated oral dosing in rodents produced no clear liver or kidney injury ^{3,4Reference 3Li L et al. · 2017ReviewResearch review on the pharmacological effects of astragaloside IV — reviewView study →Reference 4Liang Y et al. · 2023ReviewPharmacological Effects of Astragaloside IV: A Review — reviewView study →}. Because oral absorption is only ~2–3% ^{1Reference 1Gu Y et al. · 2004In vitroTransport and bioavailability studies of astragaloside IV, an active ingredient in Radix Astragali — rat/in vivo, Caco-2 in vitroView study →}, systemic exposure — and therefore systemic toxicity risk — is intrinsically limited when it is taken by mouth. The most concrete caution comes from reproductive toxicology rather than general toxicity: in an embryo-fetal development study in rats and rabbits, astragaloside IV was studied for developmental effects and, as reviewed, the broader reproductive-toxicity literature shows an inhibitory effect on female fertility and, at the higher maternal dose, delays in neonatal developmental milestones ^{13Reference 13Jiangbo Z et al. · 2009AnimalEffect of astragaloside IV on the embryo-fetal development of Sprague-Dawley rats and New Zealand White rabbits — animal reproductive toxicityView study →}. Documented human drug-interaction data for the isolated molecule are lacking; any interaction concern is theoretical and mostly relevant to the whole herb.

Dosage

Nothing here is a recommendation. There is no established human dose for the isolated compound, and the poor oral bioavailability (~2–3%) ^{1Reference 1Gu Y et al. · 2004In vitroTransport and bioavailability studies of astragaloside IV, an active ingredient in Radix Astragali — rat/in vivo, Caco-2 in vitroView study →} means research doses do not translate to an oral human regimen. For research context only: rodent studies of the isolated molecule commonly use roughly 10–40 mg/kg by injection or oral gavage in cardio-, reno- and neuroprotection models ^{11,5,9Reference 11Qu YZ et al. · 2009AnimalAstragaloside IV attenuates cerebral ischemia-reperfusion-induced increase in permeability of the blood-brain barrier in rats — rat in vivoView study →Reference 5Zhuang Z et al. · 2019Meta-analysisAstragaloside IV Exerts Cardioprotection in Animal Models of Viral Myocarditis: A Preclinical Systematic Review and Meta-Analysis — meta-analysis of animal modelsView study →Reference 9Chen J et al. · 2014AnimalAstragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats — rat in vivoView study →}, and long-term rat dosing around 10 mg/kg/day for several weeks did not produce clear organ toxicity ^{3Reference 3Li L et al. · 2017ReviewResearch review on the pharmacological effects of astragaloside IV — reviewView study →}. These are doses studied in research and are not a personal recommendation.

References